03.11.2011

Global Pharma to Pump Cash Into Russia

  Viiv Healthcare, a GlaxoSmithKline and Pfizer joint venture, will start manufacturing HIV medicines in Russia in partnership with local drugmaker Binnopharm. Agreeing a local partnership is a way for international drug companies to secure guaranteed sales in Russia, which wants to reduce dependence on imported drugs. Global drugmakers have pledged at least $1 billion in investments in Russian manufacturing, packaging and research and development. more31.10.2011

Lonza Sees Growth on Pharma Outsourcing

Swiss drugs industry supplier Lonza is set to grow underlying sales and operating profit this year despite the strong Swiss franc as it benefits from robust demand from pharmaceutical groups, particularly at a plant in China. more19.07.2011

Amgen Settles G-CSF Patent Litigation with Teva

Amgen announced that the United States District Court in Pennsylvania has entered final judgment and a permanent injunction against Teva Pharmaceutical Industries and Teva Pharmaceuticals USA prohibiting them from infringing Amgen's patents relating to human granulocyte colony-stimulating factor or G-CSF and methods for its use. more21.06.2011

Trial Set For Teva-Mylan Copaxone Lawsuit

A U.S. court on Friday denied a motion by Teva Pharmaceutical Industries for summary judgment in the Copaxone patent infringement lawsuit it has brought against Mylan Inc.     Teva is suing generic drugmaker Mylan for infringement of patents covering Teva's top-selling Copaxone multiple sclerosis drug.       more17.05.2011

Teva CEO Shlomo Yanai Says Always Looking for More Acquisitions

Teva Pharmaceutical Industries is always looking for acquisitions and will move on other potential targets when it finds a strategic fit, its top executive said on Monday. "We are scrutinizing constantly the opportunities and in due time we will move for further acquisitions when we find them a ... strategic fit," Teva CEO Shlomo Yanai said at a briefing in Tokyo. more16.05.2011

Teva to buy 57% of Taiyo for $460 Million

Teva Pharmaceutical Industries will acquire 57% of privately held Taiyo Pharmaceutical Industry for $460 million in cash and will make an offer to buy the remaining shares of the Japanese company. The deal gives Taiyo an enterprise value of $1.3 billion and is expected to be accretive to GAAP earnings within four quarters after closing, Teva said on Monday. more11.05.2011

Teva Q1 Profit Up On Higher European Sales

Teva Pharmaceutical Industries, the world's largest generic drugmaker, met forecasts with a 14% rise in quarterly earnings on strong sales growth in Europe following last year's Ratiopharm acquisition. Israel-based Teva, which last week announced a deal to acquire U.S. specialty drugmaker Cephalon for $6.8 billion, posted first-quarter earnings before certain items of $1.04 per share. Sales rose 12.1% to $4.1 billion. more04.05.2011

Teva To Buy Cephalon For $6.8 Billion

Teva Pharmaceutical Industries struck a deal to acquire U.S. specialty drugmaker Cephalon for nearly $7 billion, topping an unsolicited bid by Canada's Valeant Pharmaceuticals International. The deal would boost the brand-name business of Israel-based Teva, best known as the world's largest maker of generic drugs. Cephalon's pain, sleep and cancer drugs will help Teva reduce its reliance on the big-selling Copaxone multiple sclerosis medicine, which faces increasing competitive threats. more29.03.2011

Biosimilars Seen as a $3.7 billion Drug Market by 2015

The worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as a raft of branded drugs lose patent cover, according to market analysis firm Datamonitor. Many drugmakers are seeing potential in the business of producing copycat versions of expensive biotechnology drugs as regulators draft new rules for their approval. more08.03.2011

U.S. Supreme Court Lets 'Pay for Delay' Stand

The U.S. Supreme Court let stand a ruling that drug companies can pay rivals to delay production of generic drugs without violating federal antitrust laws. The justices refused to review a U.S. appeals court ruling that upheld the dismissal of a legal challenge to a deal between Bayer and Teva Pharmaceutical Industries' Barr Laboratories.
Bayer paid Barr to prevent it from bringing to market a version of the antibiotic drug Cipro. more